17,261 trials
Psoriasis Vulgaris · Plaque Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement — 4; 1; 0 Participants
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
AL Amyloidosis
Primary: Partial Hematologic Response (PHR) Rate — 16 Participants
Advanced Gastrointestinal Stromal Tumor (GIST)
Primary: Phase Ib Study: Number of Participants With Dose-Limiting Toxicities — 3; 8; 1; 3 Participants
Asthma
Primary: Provocative Concentration (PC) of Adenosine 5' Monophosphate (AMP) Causing a 20 Percent (%) Reduction in Forced Expiratory Volume in 1 Second (FEV1) (AMP PC20)- Dose…
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye — 26.57; 25.14; 24.48; 25.14 Millimeters of Mercury (mmHg)
Migraine Disorders
Primary: 75% Migraine Responder Rate — 38; 37; 33; 33 Participants — p=0.0330
Lower Urinary Tract Symptoms
Primary: Percentage of Participants Who Appropriately Followed the Label Instructions — 85.4 Percentage of participants
Healthy
Primary: Reflexive Cough Testing (With Urge-to-Cough) — 3; 5 units on a scale
Cystic Fibrosis
Primary: To Determine the Pharmacokinetic Profile of IV (Intravenous) and PO (Oral) Formulations of Linezolid Among Children With Cystic Fibrosis
Prader-Willi Syndrome
Primary: Post-treatment Total Score on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) — 15.9; 14.7 score on a scale
Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria — 10.8; 0.0…
Metastatic Breastcancer
Primary: Progression-free Survival — 7.9; 9.0; 8.5 months — p=0.12
Human Immunodeficiency Virus
Primary: Adverse Effects — 1 Participants
Influenza A Virus
Primary: Maximum Observed Plasma Concentration (Cmax) of Pimodivir — 5933; 5378 Nanogram per milliliter (ng/mL)